UK-based pharmaceutical giant GSK plc (NYSE: GSK) released its Q4 and full-year 2024 financial results, reporting a 7% year-on-year (YOY) growth in sales over the 12 months to GBP 31.38 billion (USD 40.1 billion). Excluding the impact of COVID-related products, the firm’s sales increased by 8% to GBP 31.36 billion. Q4 revenues stood at GBP 8.12 billion (USD 10.37 billion), up 4% YOY.
Business Segment Performance
By business segment, GSK reported strong growth across several key areas. Specialty Medicines sales reached GBP 11.81 billion, up 19%. HIV sales were GBP 7.09 billion, up 13%. Oncology sales surged to GBP 1.41 billion, up 98%. Respiratory/Immunology and Other sales were GBP 3.3 billion, up 13%. Vaccines sales were GBP 9.14 billion, down 4%. General Medicines sales were GBP 10.43 billion, up 6%.
2025 Outlook and Growth Expectations
GSK expects its 2025 turnover to increase between 3% to 5%, with core operating profit projected to rise between 6% to 8%. The company anticipates continued growth in Specialty Medicines, with low double-digit percentage increases, while Vaccines are expected to decline by a low single-digit percentage. General Medicines sales are expected to remain broadly stable.-Fineline Info & Tech
